

ULTIMATE SPORTS, INC

5 Patriot Lane, Wilbraham, MA, 01095, USA

Tel: 855-726-6224

<https://sannabis.co>

legal@sannabis.us

Annual Report

For the period ended on June 30, 2025 (the “Reporting Period”)

Outstanding Shares

The number of shares outstanding of our Common Stock was:

29,623,250 as of September 12, 2025 *(Current Reporting Period Date or More Recent Date)*

29,623,250 as of June 30, 2025 *(Current Reporting Period Date or More Recent Date)*

29,623,250 as of March 31, 2025 *(Current Reporting Period Date or More Recent Date)*

29,623,250 as of December 31, 2024 *(Current Reporting Period Date or More Recent Date)*

29,623,250 as of September 30, 2024 *(Current Reporting Period Date or More Recent Date)*

29,623,250 as of June 30, 2024 *(Current Reporting Period Date or More Recent Date)*

29,623,250 as of March 31, 2024 *(Current Reporting Period Date or More Recent Date)*

29,623,250 as of December 31, 2023 *(Current Reporting Period Date or More Recent Date)*

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company’s shell status has changed since the previous reporting period:

Yes: No:

Change in Control

Indicate by check mark whether a Change in Control¹ of the company has occurred during this reporting period:

Yes: No:

¹ “Change in Control” shall mean any events resulting in:

- (i) Any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company’s then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company’s assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

[remining of page intentionally left blank]

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

Ultimate Sports, Inc was a company filed with the Indiana Department of State as of December 5, 1988. On June 14, 2023 the Company filed Form AD-19 disclosing that the corporation is applying for a Certificate of Reinstatement from the Secretary of State, requesting a Certificate of Clearance from that departing stating all taxes and fees owed by the corporation have been paid, then the Indiana Department of State stated that all taxes, fees, interest, and penalties due have been paid or satisfied.

On June 15, 2023 the Company changed the name to Sannabis, Inc., filing the proper amendment with the State of Indiana, under Business ID 1988120359.

The Company filed with the CUSIP Global Services, the name change to Sannabis, Inc., on February 29, 2024, having been assigned CUSIP 90385W 204.

At the date of this filing the Company has still pending the name change filing to FINRA and the OTC Market as well.

Current State and Date of Incorporation or Registration: Indiana, December 5, 1988

Standing in this jurisdiction: (e.g. active, default, inactive): Active

Prior Incorporation Information for the issuer and any predecessors during the past five years:

N/A

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

N/A

List any company name change, stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

N/A

Address of the issuer's principal executive office:

5 Patriot Lane, Wilbraham, MA, 01095, USA

Address of the issuer's principal place of business:

Check if principal executive office and principal place of business are the same address:

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No:

Yes: If Yes, provide additional details below:

1) Security Information

Transfer Agent

Name: Equiniti Trust Company LLC

Phone: (919) 744-2722

Email: krista.riley@equiniti.com

Address: 1110 Centre Point Curve, Suite 101, Mendota Heights MN 55120

Publicly Quoted or Traded Securities:

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

Trading symbol:	USPS
Exact title and class of securities outstanding:	Common Stock
CUSIP:	90385W204
Par or stated value:	\$.001
Total shares authorized:	50,000,000 as of date: June 30, 2025
Total shares outstanding:	29,626,250 as of date: June 30, 2025
Total number of shareholders of record:	134 as of date: June 30, 2025

Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.

N/A

Other classes of authorized or outstanding equity securities that do not have a trading symbol:

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

Exact title and class of the security:	Preferred shares Series A
Par or stated value:	<u>No par value</u>
Total shares authorized:	25,000,000 as of date: June 30, 2025
Total shares outstanding:	1,009,000 as of date: June 30, 2025
Total number of shareholders of record:	Two (2) as of date: June 30, 2025

Please provide the above-referenced information for all other classes of authorized or outstanding equity securities.

N/A

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. For common equity, describe any dividend, voting and preemption rights.

According to the Certificate of Amendment to the Articles of Incorporation of Ultimate Sports, Inc., filed with the State of Indiana on June 4, 2024, the Company is authorized to issue 950,000,000 shares of common stock, each with a par value of \$0.001. Holders of common stock are entitled to one vote per share and may not cumulate their votes in the election of directors. The shares are not redeemable, have no conversion or preemptive rights, and are not subject to further calls or assessments once fully paid. Fully paid shares are also not subject to assessment to satisfy the Company's debts.

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

According to the Certificate of Amendment to the Articles of Incorporation of Ultimate Sports, Inc., filed with the State of Indiana on June 4, 2024, the Company is authorized to issue 10,000,000 shares of Preferred Stock, each with a par value of \$0.01. Preferred Stock may be issued in series, and the Board of Directors is authorized—subject to the limitations provided by law—to establish and designate one or more series, to fix the number of shares constituting each series, and to set the designations, powers, preferences, and relative rights of each series.

Each holder of Series A Convertible Preferred Stock shall have the right to convert each share into 10 fully paid and non-assessable shares of Common Stock. Holders of Series A Convertible Preferred Stock shall be entitled to 10 votes for each share held and may vote on all matters submitted to the shareholders of Common Stock.

For each share of Series A Convertible Preferred Stock that is to be redeemed, the Corporation shall, on the Redemption Date, pay the holder an amount in immediately available funds equal to the Liquidation Value plus all accrued dividends as of the Redemption Date.

3. Describe any other material rights of common or preferred stockholders.

N/A

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

None

2) Issuance History

*The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.***

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

No: Yes: (If yes, you must complete the table below)

[remaining of the page intentionally left blank]

Shares Outstanding as of Second Most Recent Fiscal Year End:			*Right-click the rows below and select "Insert" to add rows as needed.						
<u>Opening Balance</u>									
Date	Common:	13,953,250							
<u>12/31/2019</u>	Preferred:	1,009,000							
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
09/22/22	New issuance	400,000	Common	\$ 0.0100	No	Greg Walsh, as individual	Share purchase	Restricted	Exempt
09/22/22	New issuance	400,000	Common	\$ 0.0100	No	Greg Walsh, as individual	Share purchase	Restricted	Exempt
09/22/22	New issuance	350,000	Common	\$ 0.0100	No	Greg Walsh, as individual	Share purchase	Restricted	Exempt
09/22/22	New issuance	400,000	Common	\$ 0.0100	No	Greg Walsh, as individual	Share purchase	Restricted	Exempt
09/22/22	New issuance	200,000	Common	\$ 0.0100	No	Greg Walsh, as individual	Share purchase	Restricted	Exempt
09/22/22	New issuance	200,000	Common	\$ 0.0100	No	Greg Walsh, as individual	Share purchase	Restricted	Exempt
09/22/22	New issuance	670,000	Common	\$ 0.0075	No	Jeff D. Burns, as individual	Share purchase	Restricted	Exempt
09/22/22	New issuance	2,000,000	Common	\$ 0.0075	No	Jeff D. Burns, as individual	Share purchase	Restricted	Exempt
09/22/22	New issuance	300,000	Common	\$ 0.0100	No	David Carrero, as inividual	Share purchase	Restricted	Exempt
09/22/22	New issuance	1,000,000	Common	\$ 0.0150	No	David Carrero, as inividual	Share purchase	Restricted	Exempt
09/22/22	New issuance	500,000	Common	\$ 0.0100	No	Kevin Howell, as individual	Share purchase	Restricted	Exempt
09/22/22	New issuance	670,000	Common	\$ 0.0150	No	Jesse Ramos, as individual	Share purchase	Restricted	Exempt
09/22/22	New issuance	1,000,000	Common	\$ 0.0150	No	Jesse Ramos, as individual	Share purchase	Restricted	Exempt
09/22/22	New issuance	750,000	Common	\$ 0.0200	No	Rakeshkumar Patel, as an individual	Share purchase	Restricted	Exempt
09/22/22	New issuance	750,000	Common	\$ 0.0200	No	Rakeshkumar Patel, as an individual	Share purchase	Restricted	Exempt
09/22/22	New issuance	100,000	Common	\$ 0.0150	No	Alexander Lazarus, as an individual	Share purchase	Restricted	Exempt
12/05/23	New issuance	1,000,000	Common	\$ 0.0100	No	Rakeshkumar Patel, as an individual	Share purchase	Restricted	Exempt
12/05/23	New issuance	400,000	Common	\$ 0.0100	No	Saharie C Avillan Monroig, as an individual	Share purchase	Restricted	Exempt

12/05/23	New issuance	388,000	Common	\$	0.0002	No	Greg Walsh, as individual	Share purchase	Restricted	Exempt
12/05/23	New issuance	400,000	Common	\$	0.0083	No	Jeff D. Burns, as individual	Share purchase	Restricted	Exempt
12/05/23	New issuance	67,000	Common	\$	0.0050	No	McGhee, K as an individual	Share purchase	Restricted	Exempt
12/05/23	New issuance	100,000	Common	\$	0.0100	No	Greg Walsh, as individual	Share purchase	Restricted	Exempt
12/05/23	New issuance	750,000	Common	\$	0.0040	No	Greg Walsh, as individual	Share purchase	Restricted	Exempt
12/05/23	New issuance	400,000	Common	\$	0.0050	No	Greg Walsh, as individual	Share purchase	Restricted	Exempt
12/05/23	New issuance	125,000	Common	\$	0.0100	No	Greg Walsh, as individual	Share purchase	Restricted	Exempt
12/05/23	New issuance	350,000	Common	\$	0.0100	No	Jesse Ramos, as individual	Share purchase	Restricted	Exempt
12/05/23	New issuance	2,000,000	Common	\$	0.0075	No	Rakeshkumar Patel, as an individual	Share purchase	Restricted	Exempt

Shares Outstanding on Date of This Report:	29,623,250	
<u>Ending Balance</u> <u>06/30/2025</u>	Common: 29,623,250	
	Preferred: 1,009,000	

Example: A company with a fiscal year end of December 31st, 2024, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2023 through December 31, 2024 pursuant to the tabular format above.

Any additional material details, including footnotes to the table are below:

N/A

B. Convertible Debt

The following is a complete list of the Company's Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer's equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period.

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder. *** You must disclose the control person(s) for any entities listed.	Reason for Issuance (e.g. Loan, Services, etc.)
<u>6/18/18</u>	<u>150,000</u>	<u>150,000</u>	<u>20,021</u>	<u>Until paid</u>	<u>At 50% of market value at time of conversion.</u>	<u>Martin Maassen and Gunther Than 50% each.</u>	<u>Medical Therapeutics, LLC member interest acquisition</u>

Total Outstanding Balance: \$ 170,021

Total Shares: N/A

Any additional material details, including footnotes to the table are below:

N/A

3) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. Ensure that these descriptions are updated on the Company's Profile on www.OTCMarkets.com.

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

On May 18, 2024, the Company held a Meeting of Majority Shareholders of Sannabis, Inc. (formerly known as Ultimate Sports, Inc.). During the meeting, under Item 7: Other Business on the agenda, the majority of shareholders voted unanimously to prioritize the Sannabis business operations in Colombia over the Men's Health Service in the United States.

Following this decision, the Company completed its divestiture from Medical Therapeutics as of September 1, 2024. As a result, it significantly expanded its cooperation with Sannabis S.A., the Colombian entity, which—as previously disclosed—has become the Company's primary focus in pursuit of a merger. This process remains ongoing as of the filing of this Q2 2025 report.

B. List any subsidiaries, parent company, or affiliated companies.

Medical Therapeutics, LLC. As of September 1, 2024, and prior to the filing of this 2025-Q2, the Company assigned, transferred, and conveyed all of its rights, title, and interest in Medical Therapeutics, LLC to its former owners, Dr. Martin Maassen and Mr. Gunther Than. Accordingly, effective as of such date, Medical Therapeutics, LLC ceased to be a subsidiary of the Company. As of the date of this filing, the Company does not have any subsidiaries to report.

C. Describe the issuers’ principal products or services.

During the period covered by this disclosure corresponding to 2025-Q2, the Company has not had any commercial activity, except as included in the following paragraph referring to the activity under development with Sannabis S.A., a Colombian company in the cannabis industry.

Following the transfer of ownership of Medical Therapeutics, LLC, which occurred on September 1, 2024, the Company, together with Sannabis S.A., a Colombian corporation with which it intends to merge in the future, has engaged in various research and development activities. In collaboration with Sannabis S.A., the Company has participated in the development of new cannabis-based products pursuant to the licenses held by Sannabis S.A. for the research, development, and commercialization of such products.

4) Issuer’s Facilities

The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

At the time of filing this 2025-Q2 with the OTC Markets, the Company’s registered corporate address is 5 Patriot Lane, Wilbraham, MA, 01095, USA. The Company also shares its operational address with Sannabis S.A., its Colombian prospect affiliate, located at Cra. 83a #18–28, Comuna 17, Cali, Valle del Cauca, Colombia.

5) All Officers, Directors, and Control Persons of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
<u>Jeff Burns</u>	<u>Shareholder owner of more than 10%</u>	<u>Fort Wayne, IN</u>	<u>3,070,000</u>	<u>Common</u>	<u>10.37%</u>	<u>N/A</u>
<u>Rakeshkumar, Patel</u>	<u>Shareholder owner of more than 10%</u>	<u>Fort Wayne, IN</u>	<u>4,500,000</u>	<u>Common</u>	<u>15.19%</u>	<u>N/A</u>
<u>Juan Pablo Guzman</u>	<u>=</u>	<u>Fort Wayne, IN</u>	<u>=</u>	<u>=</u>	<u>=</u>	<u>N/A</u>

In addition, list all individuals or entities controlling 5% or more of any class of the issuer’s securities.

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
<u>Greg Walsh</u>	<u>Shareholder owner of more than 10%</u>	<u>Lawrenceville, GA</u>	<u>3,713,000</u>	<u>Common</u>	<u>12.53%</u>	<u>N/A</u>

If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.

Individual Name (First, Last) or Entity Name (Include names of control person(s) if a corporate entity)	Position/Company Affiliation (ex: CEO, 5% Control person)	City and State (Include Country if outside U.S.)	Number of Shares Owned (List common, preferred, warrants and options separately)	Class of Shares Owned	Percentage of Class of Shares Owned (undiluted)

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, log in to www.OTCIQ.com to update your company profile.

6) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

NONE

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

NONE

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

NONE

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

NONE

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

NONE

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

NONE

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

NONE

7) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, update your company profile.

Securities Counsel

Name: Christopher H Dieterich
Firm: Dieterich & Associates
Address 1: 815 Moraga Dr Ste 207
Address 2: Los Angeles, CA 90049-1633
Phone: 310-312-6888
Email: venturelaw@gmail.com

Accountant or Auditor

Name: Jorge Schcolnik (non-certified accountant)
Firm: Consultia, LLC
Address 1: 210 174th St Unit # 1809
Address 2: Sunny Isles Beach, FL 33160
Phone: (305) 401-7366
Email: jorge@consultiausa.com

Investor Relations

Name: N/A
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

All other means of Investor Communication:

X (Twitter): N/A
Discord: _____
LinkedIn: _____
Facebook: _____
[Other] _____

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: N/A
Firm: _____
Nature of Services: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

8) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: Jorge Schcolnik (non-certified accountant)
Title: Consultant
Relationship to Issuer: Consultant

B. The following financial statements were prepared in accordance with:

- IFRS
 U.S. GAAP

C. The following financial statements were prepared by (name of individual): Name:

Name: Jorge Schcolnik (non-certified accountant)
Title: Consultant
Relationship to Issuer: Consultant

Describe the qualifications of the person or persons who prepared the financial statements:⁵ Mr. Schcolnik was graduated from J.J. Urquiza Business School in the Republic of Argentina. Studied at the University of Buenos Aires, School of Economics. Was founder and owner of SV Consultores for almost 30 years in Argentina, the firm provided accounting, tax and managing services to small and medium sized companies. Once in the USA, was founder and owner of Schcolnik Consulting and currently Senior Partner of Consultia, LLC, those companies also providing bookkeeping, and other related services, for last 15 and 14 years respectively.

Provide the following qualifying financial statements:

- Audit letter, if audited;
- Balance Sheet;
- Statement of Income;
- Statement of Cash Flows;
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- Financial Notes

Financial Statement Requirements:

- Financial statements must be published together with this disclosure statement as one document.

⁵ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

- Financial statements must be “machine readable”. Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

[remaining of the page intentionally left blank]

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Juan Pablo Guzman certify that:

1. I have reviewed this Disclosure Statement for Ultimate Sports, Inc, for the period ended on June 30, 2025;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

October 14, 2025 [Date]

/s/ Juan Pablo Guzman [CEO's Signature]

(Digital Signatures should appear as “/s/ [OFFICER NAME]”)

Principal Financial Officer:

I, Jeff D Burns certify that:

1. I have reviewed this Disclosure Statement for Ultimate Sports, Inc, for the period ended on June 30, 2025;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

October 14, 2025 [Date]

/s/ Jeff D Burns [Chairman's Signature]

(Digital Signatures should appear as “/s/ [OFFICER NAME]”)

ULTIMATE SPORTS, INC
Condensed Balance Sheets
(Unaudited)

	For the Six- Months Ended on June 30, 2025	For the Twelve- Months Ended on December 31 2024
	(Unaudited)	(Unaudited)
ASSETS		
Current assets		
Cash and cash equivalents	\$ 783	\$ 1,090
Shares purchase agreement receivables	92	92
Investments	140,963	137,526
Other assets	-	-
Total current assets	141,839	138,708
PROPERTY & EQUIPMENT, NET (net of \$57 and \$ 41 depreciation as June 30, 2025, and December 31, 2024, respectively)	108	124
Total non-current assets	108	124
Total assets	\$ 141,946	\$ 138,832
 LIABILITES AND SHAREHOLDERS' EQUITY (DEFICIT)		
Current liabilities:		
Loans	1,900	1,900
SannaCoin Management Account	6,450	-
Accrued interest	20,021	17,790
Convertible notes payable - related party	150,000	150,000
Loan payable - related party -	-	-
Total current liabilities	178,371	169,690
Total liabilities	178,371	169,690
 Contingencies & Liabilities		
Shareholders loan	-	-
Shareholders' equity (deficit)		
Series A Convertible Preferred stock: 20,000,000 no par value shares authorized, and 1,009,000 shares issued and outstanding, no-par value no contribution specified, at June 30, 2025, and December 31, 2024, respectively	-	-
The Company is authorized to issue 50,000,000 shares of common stock with a par value of \$0.001 per share. As of June 30, 2025, and December 31, 2024, there were 29,623,250 and 23,643,250 shares of common stock issued and outstanding, respectively.	29,623	29,623
Additional Paid in Capital	907,919	907,919
Shares issuance pending	144,244	133,480
Accumulated deficit	(1,118,211)	(1,101,880)

Total shareholders' equity (deficit)	<u>(36,425)</u>	<u>(30,858)</u>
Total liabilities and shareholders' equity (deficit)	<u>\$ 141,946</u>	<u>\$ 138,832</u>

See accompanying notes to the condensed consolidated unaudited financial statements

[remaining of the page intentionally left blank]

ULTIMATE SPORTS, INC
Condensed Statement of Operations
(Unaudited)

	For the Three-Months Ended on June 30,		For the Six-Months Ended on June 30	
	2025	2024	2025	2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
REVENUES	\$ -	\$ -	\$ -	\$ -
COST OF SALES	-	-	-	-
GROSS PROFIT	-	-	-	-
Operating Expenses				
General and Administrative expenses	3,710	943	4,592	12,214
Officers Compensation	5,091	5,601	9,491	10,493
Depreciation	8	8	16	16
Total operating expense	8,809	6,552	14,100	22,723
Loss from operations	(8,809)	(6,552)	(14,100)	(22,723)
OTHER INCOME (EXPENSES)				
Interest Expense	(1,122)	(1,122)	(2,232)	(2,244)
Other operational income				
Total other income (expense)	(1,122)	(1,122)	(2,232)	(2,244)
Other Expenses				
Medical Therapeutics spin-off	-	-		
Assets write-off	-	-		
Total other expenses	-	-	-	
NET INCOME (LOSS)	\$ (9,931)	\$ (7,674)	\$ (16,331)	\$ (24,967)
Net income (loss) per share applicable to common stockholders - basic (continuing operations)	\$ (0.00)	\$ (0.00)	\$ (0.00)	\$ (0.00)
Net income (loss) per share applicable to common stockholders - diluted (continuing operations)	\$ (0.00)	\$ (0.00)	\$ (0.00)	\$ (0.00)
Weighted average number of common shares outstanding - basic	24,069,223	24,069,223	24,069,223	24,069,224
Weighted average number of common shares outstanding - basic	24,069,223	24,069,223	24,069,223	24,069,224

See accompanying notes to the condensed consolidated unaudited financial statements

ULTIMATE SPORTS, INC
Statements of Shareholders' Equity
For the Annual and Interim Periods from December 31, 2022, through June 30, 2025
(Unaudited)

	Common Stock		Preferred Stock		Additional Paid in Capital	Commitments & Contingencies	Warrant s	Shares issuance pending	Accumulate d Deficit	Total Shareholders' Deficit
	Shares	Amount	Shares	Amount						
BALANCE, December 31, 2022,	23,643,250	\$ 23,643	1,500,000	\$15,000	\$1,004,654	\$ (138,896)	\$ -	\$ 29,000	\$ (865,517)	\$ 67,884
Shareholders Loans						(11,104)				(11,104)
Receivable warrants outstanding										-
Shares committed not issued								1,850		1,850
Net Income (loss)									(1,925)	(1,925)
BALANCE, March 31, 2023	23,643,250	\$ 23,643	1,500,000	\$15,000	\$1,004,654	\$ (150,000)	\$ -	\$ 30,850	\$ 867,442)	\$ 56,705
Shareholders Loans						10,057				10,057
Receivable warrants outstanding										-
Shares committed not issued								20,483		20,483
Net Income (loss)									(9,635)	(9,635)

BALANCE, June 30, 2023	23,643,250	\$ 23,643	1,500,000	\$15,000	\$1,004,654	\$ (139,943)	\$ -	\$ 51,333	\$ (877,077)	\$ 77,610
Shareholders Loans						1,520				1,520
Common stock issued										-
Equity reclass										-
Shares committed not issued										-
Net Income (loss)									(4,009)	(4,009)
BALANCE, September 30, 2023	23,643,250	\$ 23,643	1,500,000	\$15,000	\$1,004,654	\$ (138,423)	\$ -	\$ 51,333	\$ (881,086)	\$ 75,120
Shareholders Loans						(13)				(13)
Common stock issued	5,980,000	5,980			38,265					44,245
Equity reclasses										-
Shares committed not issued								(2,553)		(2,553)
Adjustment										2
Net Income (loss)									(28,764)	(28,764)
BALANCE, December 31, 2023	29,623,250	\$ 29,623	1,500,000	\$15,000	\$1,042,919	\$ (138,436)	\$ -	\$ 48,780	\$ (909,850)	\$ 88,037
Guarantee null						150,000				150,000

Preferred shares voided			(1,500,000)	(15,000)	(135,000)						(150,000)
-------------------------	--	--	-------------	----------	-----------	--	--	--	--	--	-----------

BALANCE, December 31, 2023 - AMENDED & RESTATED	29,623,250	\$ 29,623	-	\$ -	\$ 907,919	\$ 11,564	\$ -	\$ 48,780	\$ (909,850)	\$ 88,037
--	------------	-----------	---	------	------------	-----------	------	-----------	--------------	-----------

Shares committed not issued								\$ 21,000		21,000
Net Income (loss)									(17,293)	(17,293)

BALANCE, March 31, 2024	29,623,250	\$ 29,623	-	\$ -	\$ 907,919	\$ 11,564	\$ -	\$ 69,780	\$ (927,144)	\$ 91,743
--------------------------------	------------	-----------	---	------	------------	-----------	------	-----------	--------------	-----------

Shares committed not issued								\$ 23,409		23,409
Net Income (loss)									(7,674)	(7,674)

BALANCE, June 30, 2024	29,623,250	\$ 29,623	-	\$ -	\$ 907,919	\$ 11,564	\$ -	\$ 93,189	\$ (934,818)	\$ 107,478
-------------------------------	------------	-----------	---	------	------------	-----------	------	-----------	--------------	------------

Medical Therapeutics spin-off Shareholders' loan						\$ (11,564)			\$ 15,634	15,634
Shares committed not issued								\$ 9,917		9,917

Net Income (loss)										(168,640)	(168,640)
BALANCE, September 30, 2024	29,623,250	\$ 29,623	-	\$ -	\$ 907,919	\$ -	\$ -	\$ 103,106	\$ (1,087,824)	\$ (47,176)	
Medical Therapeutics spin-off Shareholders' loan Shares committed not issued								\$ 30,374			30,374
Net Income (loss)									(14,056)	(14,056)	
BALANCE, December 31, 2024	29,623,250	\$ 29,623	-	\$ -	\$ 907,919	\$ -	\$ -	\$ 133,480	\$ (1,101,880)	\$ (30,858)	
Medical Therapeutics spin-off Shareholders' loan Shares committed not issued								\$ 4,574			4,574
Net Income (loss)									(6,399)	(6,399)	
BALANCE, March 31, 2025	29,623,250	\$ 29,623	-	\$ -	\$ 907,919	\$ -	\$ -	\$ 138,054	\$ (1,108,279)	\$ (32,684)	
Medical Therapeutics spin-off											-

ULTIMATE SPORTS, INC
Condensed Statements of Cash-Flows
(Unaudited)

	For the Six- Months Ended on June 30 2025 (Unaudited)	For the Twelve- Months Ended on December 31 2024 (Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net Income (Loss)	\$ (16,331)	(207,663)
Adjustment to reconcile net income (loss) to net cash provided operating activities:		
Depreciation and amortization expense	16	33
Change in operating assets and liabilities:		
Accounts payable and accrued expenses	6,450	-
Shares purchase agreement receivables	-	-
Accrued interest	2,231	4,513
Accrued interest related party	-	-
Assets write off (Medical Therapeutics split-off)		15,633
Credit Card Payables	-	-
Goodwill		139,800
Inventory	-	-
Notes Payable	-	-
Notes Receivable	-	-
Other assets write off	-	-
Other current assets	-	(29,113)
Payroll and payroll taxes payable	-	-
Taxes payable	-	-
Security Deposits	-	-
Net cash provided by operating activities	(7,634)	(76,797)
CASH FLOWS FROM INVESTING ACTIVITIES:		
Cash paid for assets acquisition	(3,437)	-
Net cash used in investing activities	(3,437)	-
CASH FLOWS FROM FINANCING ACTIVITIES		
Warrants outstanding	-	-
Financial loans payable	-	-
Commitment & Contingencies-Shaholders Loan	-	(11,564)
Proceeds from preferred stock	-	-

Proceeds from common stock issuance	-	-
Proceeds from loans	-	-
Loans payment	-	(3,000)
Proceeds from notes payable	-	-
Shares issuance pending	10,764	84,700
Net Cash provided by financing activities	<u>10,764</u>	<u>70,136</u>
NET CHANGE IN CASH	(307)	(6,661)
CASH, beginning of period	1,090	7,751
CASH, end of period	<u>\$ 783</u>	<u>1,090</u>
SUPPLEMENTAL DISCLOSURES:		
Cash paid for income taxes	\$ -	-
Cash paid for interest	<u>\$ -</u>	<u>-</u>

See accompanying notes to the condensed consolidated unaudited financial statements

[remaining of the page intentionally left blank]

ULTIMATE SPORTS, INC
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the period ended on June 30, 2025

NOTE 1 – ORGANIZATION AND NATURE OF THE BUSINESS

Ultimate Sports, Inc (“USPS, the “Company”, “we”, “our”, “ours” or “us”) is a publicly traded company that provides innovative strategic and financing resources including mergers and acquisitions (“M&A”) as well as companies acquisitions for business development as part of the Company.

Ultimate Sports, Inc., was founded on December 5, 1988, and chartered in the State of Indiana, under Secretary of State File 1988120359.

On June 15, 2018, the Company acquired Medical Therapeutics, LLC., who owned and operated clinics that provided medical advice and procedures that benefit the health and medical needs of men, the Company acquired the entire company, its assets, business, and intellectual property. Dr. Martin Maassen, one of the Company board members, being disciplined in the Medical Business had been tasked to diversify and increase the business of USPS.

On June 15, 2023, the Company changed the name to Sannabis, Inc., filing # 9916149 State of Indiana.

On February 29, 2024, Cusip Global Services confirmed as an issuer to Sannabis, Inc., Cusip # 90385W 204, ISIN #: US90385W2044, ISO CFI: ESVUFR, FISN: Sannabis Inc/SH CL B.

Ultimate Sports, Inc., is listed in the OTC Markets, under the symbol USPS, qualified as Expert Market. By the time this filing is submitted the OTC Market may qualified USPS as OTCQI.

Divestiture of Medical Therapeutics, LLC (a Colorado entity)

On September 1, 2024, the Company completed the divestiture of its subsidiary, which provided licensed physicians to diagnose and treat male health and wellness remotely provided by Dr. Martin Maassen out of his personal location, to their former stakeholders Dr. Maassen and M. Gunther Than for no consideration. The transaction resulted in a loss of \$ 157,700, which is included in Other Expenses- Medical Therapeutics spin-off in the Consolidated Statements of Income for the period ended on September 30, 2024.

The disposed component did not represent a strategic shift that had, or will have, a major effect on the Company's operations or financial results. Therefore, in accordance with ASC 205-20, the divestiture does not meet the criteria for classification as a discontinued operation.

As a result, the related results of operations, assets, and liabilities associated with the divested component are presented within continuing operations for all periods presented.

The Company previously decided to shift its focus toward the cannabis industry through a potential partnership with Sannabis S.A., which possesses the necessary infrastructure in Colombia. This strategic pivot effectively sidelined the activities of Medical Therapeutics, primarily due to its inability to generate revenue. For instance, in 2024, Medical Therapeutics recorded zero revenue, and in 2023, it earned only \$1,893.

Management maintains that Medical Therapeutics has never contributed funds to the Company and cannot reasonably be considered a significant asset. As outlined in *Discontinued Operations* (Ernst & Young LLP, revised edition May 2019), a disposal qualifies as a discontinued operation only if certain criteria are met. Specifically, *Criterion 3 states that the component must represent a strategic shift that has or will have a major effect on the entity's operations and financial results* (see section 2.3).

Given the above, management believes that no further justification is required regarding the treatment of Medical Therapeutics under discontinued operations.

The Company continues to evaluate its business portfolio to support strategic priorities and will assess classification of future divestitures in accordance with applicable accounting guidance.

NOTE 2: GOING CONCERN

These consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the foreseeable future. As of June 30, 2025, the Company has an accumulated deficit of \$ 1,118,211 since inception. This raises substantial doubt about the Company's ability to continue as a going concern.

Management's plans include raising capital through the equity markets to fund operations and eventually generate revenue through its business; however, there can be no assurance that the Company will be successful in such activities. These consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classifications of the liabilities that might be necessary should the Company be unable to continue as a going concern.

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

The accompanying did not consolidate financial statements of Ultimate Sports, Inc., because the Company has no subsidiaries by the period ended on June 30, 2025.

Basis of Accounting

The Company prepared the accompanying financial statements in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP"). The financial statements include the operations, assets, and liabilities of the Company. In the opinion of the Company's management, the accompanying financial statements contain all adjustments, consisting of normal recurring accruals, necessary to fairly present the accompanying financial statements.

Use of Estimates

The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the period in which they are determined to be necessary. In preparing the financial statements, management makes estimates and assumptions regarding: the adequacy of the allowance for doubtful accounts; the realization of deferred taxes; the measurement of equity-based compensation; and other matters that affect the reported amounts and disclosures of contingencies in the financial statements.

Cash and Cash Equivalents

The Company considers all investments with a maturity date of three months or less when purchased to be cash equivalents. The Company had cash in the amount of \$ 783 and \$ 1,090 as of June 30, 2025, and December 31, 2024, respectively.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivables are recorded at the invoiced amount, net of an allowance for doubtful accounts. The Company performs on-going credit evaluations of its customers and adjusts credit limits based upon payment history and the customer's current credit worthiness, as determined by the review of their current credit information; and determines

the allowance for doubtful accounts based on historical write-off experience, customer specific facts and general economic conditions that may affect a client’s ability to pay.

Accounts receivables are stated at the amount management expects to collect from outstanding balances. The Company charges off receivable balances against the allowance for doubtful accounts when collection efforts have been exhausted, and the amounts are deemed uncollectible. Receivables are considered past due based on the age of the balance and recent payment history.

As of June 30, 2025, and December 31, 2024, the Company reported gross accounts receivable of \$92 and no allowance for doubtful accounts, resulting in net accounts receivable of \$92 for both periods. No bad debt expense was recorded during the three-months ended June 30, 2025, or the year ended December 31, 2024.

Property and Equipment

Property and equipment are recorded at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation of property and equipment is computed by the straight-line method (after considering their respective estimated residual values shown in the table below) over the estimated useful lives of the respective assets. Upon the sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts, and any gain or loss is reflected in statements of operations. During the six months ended June 30, 2025, the Company did not acquire or dispose of any fixed assets.

As of June 30, 2025, and December 31, 2024, the Company reported gross fixed assets of \$165. Accumulated depreciation was \$57 and \$41, respectively, resulting in net fixed assets of \$108 and \$124 as of those dates.

Depreciation expense is recorded using the straight-line method over the estimated useful lives of the assets.

Account	Acquisition		Depreciation				Net Value as of 06/30/25
	Date	Cost	Accumulated as of	Expenses	Expenses	Accumulated as of	
			12/31/24	3/31/25	6/30/25	6/30/25	
1910000 - Furniture & Equipment - Printer -	10/5/23	165.00	40.89	8.14	8.23	57.25	107.75
Total:		\$ 165	\$ 41	\$ 8	\$ 8	\$ 57	\$ 108

Loans Payable

The Company assumed certain liabilities along with the acquisition of Medical Therapeutics, Inc., such liabilities must be considered as Related Party Liabilities. The balance of this account as of June 30, 2025, and December 31, 2024, was \$1,900 and \$ 1,900 respectively, this debt did not recognize accrued interest and has no maturity term.

Account Payable

On April 1, 2025, the Company, through a Board Resolution, resolved the following:

(i) to act as a facilitator for the launch of **SannaCoin (SOL: SANNA)** on the Solana network, intended to be used as a utility token for purchasing products from Sannabis S.A.S.—the Colombian company targeted for a future merger—on a global scale; and

(ii) to authorize the use of the Company’s existing bank accounts for administrative purposes related to SannaCoin.

Under these terms, the Company received funds from the sale of SannaCoin tokens and used them to pay authorized expenses and vendors associated with the project. The balance in the account reflects an amount owed by Ultimate Sports, Inc. to SannaCoin, arising from these transactions.

Beneficial Conversion Feature

If the conversion features of conventional convertible debt provide for a rate of conversion that is below market value at issuance, this feature is characterized as a beneficial conversion feature ("BCF"). A Beneficial Conversion *Options*. In those circumstances, the convertible debt is recorded net of the discount related to the BCF, and the Company amortizes the discount to interest expense over the life of the debt using the effective interest method.

Embedded Conversion Features

The Company evaluates embedded conversion features within convertible debt under ASC 815 Derivatives and Hedging to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in earnings. If the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20 Debt with Conversion and Other Options for consideration of any beneficial conversion features.

Derivative Financial Instruments

Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their fair value for accounting purposes. In determining the appropriate fair value, the Company shall use the Black-Scholes option-pricing model. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and, further, if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments.

Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black Scholes option-pricing model.

Fair Value of Financial Instruments

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on our principal or, in the absence of a principal, most advantageous market for the specific asset or liability.

U.S. generally accepted accounting principles provide for a three-level hierarchy of inputs to valuation techniques used to measure fair value, defined as follows:

Level 1: Inputs that are quoted prices (unadjusted) for identical assets or liabilities in active markets that the entity can access.

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability, including:

- quoted prices for similar assets or liabilities in active markets;
- quoted prices for identical or similar assets or liabilities in markets that are not active;
- inputs other than quoted prices that are observable for the asset or liability; and
- inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3: Inputs that are unobservable and reflect management's own assumptions about the inputs market participants would use in pricing the asset or liability based on the best information available in the circumstances (e.g., internally derived assumptions surrounding the timing and amount of expected cash flows).

Our financial instruments consist of cash, accounts receivable, accounts payable, and debt. We have determined that the book value of our outstanding financial instruments as of June 30, 2025, and December 31, 2024, approximates the fair value due to their short-term nature.

Items recorded or measured at fair value on a recurring basis in the accompanying consolidated financial statements consisted of the following items as of June 30, 2025, and December 31, 2024:

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
				June 30, 2025
Convertible Notes Payable	\$ -	\$ -	\$ 150,000	\$ 150,000
	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
				December 31, 2024
Convertible Notes Payable	\$ -	\$ -	\$ 150,000	\$ 150,000

Revenue Recognition

Effective January 1, 2018, the Company adopted the Financial Accounting Standards Board (“FASB”) standard update ASU 2014-09, “Revenue from Contracts with Customers,” (“Topic 606”) which provides a principles-based, five-step approach to measure and recognize revenue from contracts with customers. Revenue is recognized when the following criteria are met:

- Identification of the contract, or contracts, with a customer;
- Identification of the performance obligations in the contract;
- Determination of the transaction price;
- Allocation of the transaction price to the performance obligations in the contract; and
- Recognition of revenue when, or as, we satisfy performance obligation.

The adoption of this guidance did not have a material impact on the Company’s consolidated statements of operations, cash flows, shareholders’ equity (deficit), or balance sheets as of the adoption date.

The Company's revenues have been generated primarily through the services provided to third parties. The terms of these agreements generally consist of a pre-payment by credit cards, which normally takes 24 to 48 hours to be deposited in the designated bank account while normally delivery happens at the time the merchant approves the card transaction.

For the six-months period ended June 30, 2025, all met the above criteria or in exceptional cases only involvement was to sell to some of the end users at pricing that is consistent with market transactions, thereby allowing for the recognition of revenue for the revenue on such transactions upon delivery. The Company registered sales of \$0 and \$ 1,090 as of June 30, 2025, and June 30, 2024 respectively

We periodically review for any expected period of substantial involvement under the agreements that provide for non-refundable up-front payments and fees. If applicable, we will adjust the amortization periods when appropriate to reflect changes in assumptions relating to the duration of our expected involvement.

Income Taxes

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Additionally, the recognition of future tax benefits, such as net operating loss carryforwards, is required to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are determined using enacted tax rates

expected to apply to taxable income in the years in which the assets and liabilities are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income tax expense in the period that includes the enactment date.

In the event the future tax consequences of differences between the financial reporting bases and the tax bases of the Company's assets and liabilities result in deferred tax assets, an evaluation of the probability of being able to realize the future benefits indicated by such asset is required. A valuation allowance is provided for the portion of the deferred tax asset when it is more likely than not that some or all of the deferred tax asset will not be realized. In assessing the realizability of the deferred tax assets, management considers the scheduled reversals of deferred tax liabilities, projected future taxable income, and tax planning strategies.

The Company files income tax returns in the United States, which are subject to examination by the tax authorities in these jurisdictions. Generally, the statute of limitations related to the Company's federal and state income tax return is three years. The state impact of any federal changes for prior years remains subject to examination for a period up to five years after formal notification to the states.

Management has evaluated tax positions in accordance with ASC 740, *Income Taxes*, and has not identified any significant tax positions, other than those disclosed. All the Company's tax years since inception remain subject to examination by Federal and State jurisdictions.

Earnings Per Share

Basic net income per common share ("*Basic EPS*") excludes dilution and is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share ("*Diluted EPS*") reflects the potential dilution that could occur if stock options or other contracts to issue shares of common stock were exercised or converted into common stock. The computation of Diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect on net income per common share.

	For the Six-Months Ended on June 30,	
	2025	2024
Numerator		
Net income (loss) applicable to common shareholders	\$ (16,331)	\$ (24,967)
Denominator		
Weighted average common shares outstanding, basic	24,069,223	24,069,223
Convertible preferred stock		
Convertible promissory notes	-	-
Weighted average common shares outstanding, diluted	<u>24,069,223</u>	<u>24,069,223</u>
Net Income per share - Basic	<u>\$ (0.00)</u>	<u>\$ -</u>
Income per shares - Diluted	<u>\$ (0.00)</u>	<u>\$ -</u>

NOTE 5: NOTES PAYABLE

Convertible Notes Payable Related Parties

On June 18, 2018, the Company entered into a note with Medical Therapeutics' principals, Dr. Martin Maassen and Mr. Gunther Than, who are the Holders at 50% each. The Note is convertible into USPS' shares of common stock, at the then effective Conversion Rate, upon the USPS sale of all or substantially all, of the assets, or the merger, consolidation or liquidation of USPS where USPS is not in control of the merged, consolidated or liquidated entity or

other change in control of USPS (except for mergers such as those used to effect changes in the state of incorporation or a conversion of USPS to another legal entity) (any of such events a “Change in Control”), where the valuation of the cash, securities and/or other consideration received by USPS or its stockholders in such transaction exceeds \$30,000,000. Immediately upon such conversion, Holders shall surrender the Note at the USPS offices against delivery of that number of USPS’ shares equal to the quotient of (x) the outstanding principal balance due and owing under the Note on the Conversion Date, divided by the Conversion Rate. The term “Conversion Rate” shall mean 50% of the market value at time of conversion per share. The Note accrued interest of 3% compounded annually. The balance of the note as of June 30, 2025 and December 31, 2024, for principal and interest is \$150,000 and \$ 20,021 and \$150,000 and \$17,790 respectively.

NOTE 6: EQUITY

The Company has at the time of this filing 29,623,250 shares of common stock issued and outstanding.

On November 8, 2021, the Company signed a Stock Purchase Agreement with unaffiliated individual investor, selling 1,000,000 shares of common stock at \$.015 per shares. The shares were not issued at the period ended on December 31, 2021, therefore were recorded in the financials as Shares issuance pending as of December 31, 2021.

On November 8, 2021, the Company signed a Stock Purchase Agreement with unaffiliated individual investor, under which granted for the term of 24 months the purchase of additional 1,000,000 shares of common stock at \$.015/share.

On November 8, 2021, the Company signed a Stock Purchase Agreement with unaffiliated individual investor, selling 1,000,000 shares of common stock at \$.015 per shares. The shares were not issued at the period ended on December 31, 2021; therefore, were recorded in the financials as Shares issuance pending as of December 31, 2021.

On November 8, 2021, the Company signed a Stock Purchase Agreement with unaffiliated individual investor, under which granted for the term of 24 months the purchase of additional 1,000,000 shares of common stock at \$.015/share.

Note On December 10, 2021, the Company signed a Stock Purchase Agreement with unaffiliated individual investor selling 200,000 shares of common stock at \$.01 per shares. The shares were not issued at the period ended on December 31, 2021, therefore were recorded in the financials as Shares issuance pending as of December 31, 2021.

On December 31, 2021, the Company signed a Stock Purchase Agreement with unaffiliated individual investor selling 200,000 shares of common stock at \$.01 per shares. The shares were not issued at the period ended on December 31, 2021, therefore were recorded in the financials as Shares issuance pending as of December 31, 2021.

On January 15, 2022, the Company signed a Stock Purchase Agreement with an unaffiliated individual investor selling 670,000 restricted shares of common stock at \$.015 per share. As of the date of this disclosure, these shares have not been issued.

On February 14, 2022, the Company signed a Stock Purchase Agreement with an individual investor selling 400,000 restricted shares of common stock at \$.01 per share. As of the date of this disclosure, these shares have not been issued.

On February 22, 2022, the Company signed a Stock Purchase Agreement with unaffiliated individual investor selling 670,000 restricted shares of common stock at \$.0075 per share. As of the date of this disclosure, these shares have not been issued.

On February 23, 2022, the Company entered into a service agreement with a Web Developer for a period of 12 months commencing on March 1, 2022. The Company will issue restricted shares of its Common Stock to the Service Provider Quarterly as billed, up to \$ 1000 per month, unless later agreed by Parties otherwise. The shares will be issued at 60% of the lowest closing price for 20 days prior to the date of the Quarterly invoice. The first invoice will be due on June 1, 2022.

On March 1, 2022, the Company signed a Stock Purchase Agreement with an unaffiliated individual investor selling 750,000 restricted shares of common stock at \$.02 per share. As of the April 28, 2022, these shares have not been issued.

On April 27, 2022, the Company signed a Stock Purchase Agreement with an unaffiliated individual investor selling 400,000 shares at a purchase price of \$.01, a consideration of \$4,000. As of August 17, 2022, these shares have not been issued.

On May 24, 2022, the Company signed a Stock Purchase Agreement with an unaffiliated individual investor selling 750,000 restricted shares of common stock at \$.02 per share, a consideration of \$15,000. As of August 17, 2022, these shares have not been issued.

On June 7, 2022, the Company signed a Stock Purchase Agreement with an unaffiliated individual investor selling 350,000 shares at a purchase price of \$.01, a consideration of \$3,500. As of August 17, 2022, these shares have not been issued.

On September 22, 2022, the Company issued 400,000 shares of common stock, par value \$0.001 at \$0.01 per share, to an unaffiliated individual investor.

On September 22, 2022, the Company issued 400,000 shares of common stock, par value \$0.001 at \$0.01 per share, to an unaffiliated individual investor.

On September 22, 2022, the Company issued 350,000 shares of common stock, par value \$0.001 at \$0.01 per share, to an unaffiliated individual investor.

On September 22, 2022, the Company issued 400,000 shares of common stock, par value \$0.001 at \$0.01 per share, to an unaffiliated individual investor.

On September 22, 2022, the Company issued 200,000 shares of common stock, par value \$0.001 at \$0.01 per share, to an unaffiliated individual investor.

On September 22, 2022, the Company issued 200,000 shares of common stock, par value \$0.001 at \$0.01 per share, to an unaffiliated individual investor.

On September 22, 2022, the Company issued 200,000 shares of common stock, par value \$0.001 at \$0.01 per share, to an unaffiliated individual investor.

On September 22, 2022, the Company issued 670,000 shares of common stock, par value \$0.001 at \$0.0075 per share, to an unaffiliated individual investor.

On September 22, 2022, the Company issued 2,000,000 shares of common stock, par value \$0.001 at \$0.0075 per share, to an unaffiliated individual investor.

On September 22, 2022, the Company issued 300,000 shares of common stock, par value \$0.001 at \$0.01 per share, to an unaffiliated individual investor.

On September 22, 2022, the Company issued 1,000,000 shares of common stock, par value \$0.001 at \$0.015 per share, to an unaffiliated individual investor.

On September 22, 2022, the Company issued 750,000 shares of common stock, par value \$0.001 at \$0.02 per share, to an unaffiliated individual investor.

On September 22, 2022, the Company issued 750,000 shares of common stock, par value \$0.001 at \$0.02 per share, to an unaffiliated individual investor.

On September 22, 2022, the Company issued 100,000 shares of common stock, par value \$0.001 at \$0.015 per share, to an unaffiliated individual investor.

On December 15, 2023, the Company issued 3,000,000 shares of common stock, par value \$0,001 at \$0,01 per share, to an affiliated individual investor.

On December 15, 2023, the Company issued 400,000 shares of common stock, par value \$0,001 at \$0,01 per share, to an unaffiliated individual investor.

On December 15, 2023, the Company issued 67,000 shares of common stock, par value \$0,001 at \$0,005 per share, to an unaffiliated individual investor.

On December 15, 2023, the Company issued 1,763,000 shares of common stock, par value \$0,001 at \$0,01 per share, to an affiliated individual investor.

On December 15, 2023, the Company issued 400,000 shares of common stock, par value \$0,001 at \$0,0083 per share, to an affiliated individual investor.

On December 15, 2023, the Company issued 350,000 shares of common stock, par value \$0,001 at \$0,01 per share, to an unaffiliated individual investor.

NOTE 7: COMMITMENTS AND CONTINGENCIES.

During the normal course of business, the Company may be exposed to litigation. When the Company becomes aware of potential litigation, it evaluates the merits of the case in accordance with ASC 450-20-50, *Contingencies*. The Company evaluates its exposure to the matter, possible legal or settlement strategies and the likelihood of an unfavorable outcome. If the Company determines that an unfavorable outcome is probable and can be reasonably estimated, it establishes the necessary accruals.

NOTE 8: SUBSEQUENT EVENTS AFTER JUNE 30, 2025

The Company has evaluated subsequent events that occurred through the date of the filing of the Company's period ended on June 30, 2025, and has determined the following subsequent events:

On September 1, 2025, the Company applied for the name change from Ultimate Sports, Inc to Sannabis, Inc, with FINRA, Case: CAS22016G4W3B3F6, the process is under development.

Expert Market Status and Filing Delays: The Company was moved to the Expert Market due to its failure to file timely financial statements and related disclosures. This delay was primarily the result of limited working capital, which prevented the Company from completing the necessary accounting and compliance work. As of the date of submission of this Quarterly Report for the period ended on June 30, 2025, the Company is actively addressing these deficiencies, and management expects that it will regain eligibility for quotation on the OTCQB or OTCID tier in the near term.